Latest Conference Coverage

The new registry will collect routine clinical practice data from the care of patients with Alzheimer disease who are taking an FDA-approved disease-modifying therapy.

Despite the cohort only consisting of 3 patients with Alzheimer disease, autologous cellular therapy data highlighted the potential of the treatment’s results on cognitive assessments such as Montreal Cognitive Assessment.

The data, which suggest that a lessened decline in cognition and function was correlated with a reduction in plasma p-tau181 levels in those with Alzheimer disease treated with aducanumab (Aduhelm; Biogen), were presented at CTAD 2021.

Study of semorinemab in a larger mITT population confirmed statistically significant reduction in rate of cognitive decline in patients with Alzheimer disease, compared with placebo, but failed to achieve other end points.

Outlining the development of the CHIMES trial in multiple sclerosis, the founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center spoke on tactics to get underrepresented populations involved. [WATCH TIME: 2 minutes]

The founder and CEO of Joi Life Wellness Group Multiple Sclerosis Center outlined the motivations behind the trial, as well as potential reasons for underrepresentation. [WATCH TIME: 2 minutes]

The chief of the Multiple Sclerosis Division, Perelman School of Medicine at the University of Pennsylvania emphasized current recommendations, which suggest patients with MS get vaccinated for COVID-19. [WATCH TIME: 3 minutes]

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]

The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine, University of Pennsylvania, discussed recommendations for COVID-19 vaccination in this patient population, specifically for those on disease-modifying therapies. [WATCH TIME: 2 minutes]

Mona Bostick, RDN, LDN, MSCS, gave her perspective on nutrition in MS, popular elimination diets, and the role registered dietitians can play in the multidisciplinary care model.

The director of the Multiple Sclerosis Achievement Center outlined the design of the wellness programs, which are held in 2 different formats. [WATCH TIME: 4 minutes]

Amit Bar-Or, MD, FRCPC, FAAN, FANA, commented on his presentations at CMSC 2021, one of which focused on COVID-19 vaccination, which experts do not believe poses risks for those on disease-modifying therapies.

The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]

Brian Hutchinson, PT, MSCS, commented on the Multiple Sclerosis Achievement Center program, which includes patient data spanning a 3-year period.

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]

Vikram Bhise, MD, outlined useful questions to include in conversation when discussing the transition to adulthood for patients with pediatric multiple sclerosis.

Vikram Bhise, MD, discussed findings recently presented at CMSC 2021, where teenagers with multiple sclerosis were interviewed to identify perceptions of QOL during the transition to adulthood.

The founder of Food Matters 365, in Greensboro, North Carolina, commented on the benefits of adding a dietitian to the healthcare team for patients with multiple sclerosis. [WATCH TIME: 3 minutes]

The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School discussed findings from a qualitative study that aimed at understanding priorities and concerns within this patient population during a transitional period.

The registered dietitian at Food Matters 365 in Greensboro, North Carolina, discussed the role nutrition can play in treating comorbidities, sharing her thoughts on popular elimination diets. [WATCH TIME: 2 minutes]

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, and a research nonclinical psychologist, University of Michigan Medicine, offered insight into the multidisciplinary approach to managing fatigue for patients with multiple sclerosis.

Data presented at CMSC 2021 suggest worse COVID-19 outcomes were associated with patients with neuromyelitis optica spectrum disorder and other comorbidities.

In total, 72% of responders reported spasticity as a top 5 most problematic symptom, with 17% ranking it as the single most difficult symptom of MS to manage.

The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to some of the newer biomarkers and measures being assessed in the clinical management of multiple sclerosis. [WATCH TIME: 3 minutes]

The director of the Multiple Sclerosis Experimental Therapeutics Program at Johns Hopkins Medicine offered insight on the TREAT-MS trial to attendees of the CMSC 2021 annual meeting.

Data further investigated the impact of how individual disease-modifying therapies affect outcomes for this patient population.

The post-doctoral scholar at the University of Iowa outlined his presentation at CMSC 2021 which focused on the use of elimination diets to improve symptoms of MS. [WATCH TIME: 2 minutes]